Vanguard Investments Australia
LEGN icon

Vanguard Investments Australia’s Legend Biotech LEGN Stock Holding History

Vanguard Investments Australia’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Hold
13,130
– – ﹤0.01% 1790
2026
Q1 		$238K Buy
+13,130
New +$250K ﹤0.01% 1956

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Vanguard Investments Australia's LEGN Position: Q2 2026 in Review

Vanguard Investments Australia held its Legend Biotech (LEGN) position steady in Q2 2026 at 13,130 shares worth $379K. The position accounts for ﹤0.01% of the portfolio, ranked #1790.

Vanguard Investments Australia first reported a position in LEGN in Q1 2026 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Vanguard Investments Australia held 13,130 shares of Legend Biotech worth $379K as of Q2 2026.
  • Vanguard Investments Australia left its Legend Biotech share count unchanged in Q2 2026.
  • Legend Biotech made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1790 holding.
  • Vanguard Investments Australia first reported a position in Legend Biotech in Q1 2026 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.